Candel Therapeutics (CADL) Net Income towards Common Stockholders (2020 - 2025)
Candel Therapeutics' (CADL) quarterly Net Income towards Common Stockholders came in at -$16.1 million in Q4 2025, down 94.95% year-on-year from -$318.3 million in Q4 2024, and down 29.41% quarter-over-quarter from -$12.4 million in Q3 2025.
Candel Therapeutics (CADL) Net Income towards Common Stockholders (2020 - 2025) Analysis & Trends
Candel Therapeutics has disclosed Net Income towards Common Stockholders across 6 years of filings, most recently posting -$16.1 million for Q4 2025.
- Net Income towards Common Stockholders for Q4 2025 came in at -$16.1 million, down 94.95% year-over-year; the trailing twelve-month figure through Dec 2025 was -$46.5 million (down 35.19% YoY), and the FY2025 annual result was -$46.5 million, down 35.19% from the prior year.
- Net Income towards Common Stockholders came in at -$16.1 million for Q4 2025 at Candel Therapeutics, down from -$12.4 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$4.7 million in Q1 2021 to a low of -$16.1 million in Q4 2025.
- The 5-year median for Net Income towards Common Stockholders is -$9.0 million (2023), against an average of -$9.0 million.
- Across the five-year window, Net Income towards Common Stockholders slumped 197.01% in 2021 and increased 22.08% in 2024, its largest moves.
- Candel Therapeutics' Net Income towards Common Stockholders stood at -$7.8 million in 2021, then retreated by 1.6% to -$7.9 million in 2022, then tumbled by 34.3% to -$10.6 million in 2023, then climbed by 22.08% to -$8.2 million in 2024, then tumbled by 94.95% to -$16.1 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$16.1 million (Q4 2025), -$12.4 million (Q3 2025), and -$10.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Candel Therapeutics | 453.59 Mn | 453.59 Mn | - | -16.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -16.07 Mn |
| Sep 30, 2025 | -12.42 Mn |
| Jun 30, 2025 | -10.49 Mn |
| Mar 31, 2025 | -7.50 Mn |
| Dec 31, 2024 | -8.24 Mn |
| Sep 30, 2024 | -9.01 Mn |
| Jun 30, 2024 | -8.90 Mn |
| Mar 31, 2024 | -8.23 Mn |
| Dec 31, 2023 | -10.58 Mn |
| Sep 30, 2023 | -9.03 Mn |
| Jun 30, 2023 | -9.77 Mn |
| Mar 31, 2023 | -9.53 Mn |
| Dec 31, 2022 | -7.88 Mn |
| Sep 30, 2022 | -9.06 Mn |
| Jun 30, 2022 | -9.12 Mn |
| Mar 31, 2022 | -9.16 Mn |
| Dec 31, 2021 | -7.75 Mn |
| Sep 30, 2021 | -8.04 Mn |
| Jun 30, 2021 | -5.32 Mn |
| Mar 31, 2021 | -4.67 Mn |